What is Zacks Research’s Forecast for Omnicell Q3 Earnings?

Omnicell, Inc. (NASDAQ:OMCL) – Research analysts at Zacks Research cut their Q3 2026 EPS estimates for shares of Omnicell in a note issued to investors on Friday, August 14th. Zacks Research analyst Team now anticipates that the company will earn $0.25 per share for the quarter, down from their previous forecast of $0.27. Zacks Research has a “Strong Sell” rating on the stock. The consensus estimate for Omnicell’s current full-year earnings is $1.30 per share. Zacks Research also issued estimates for Omnicell’s Q4 2026 earnings at $0.07 EPS, FY2026 earnings at $1.49 EPS, Q1 2027 earnings at $0.25 EPS, Q2 2027 earnings at $0.23 EPS, Q3 2027 earnings at $0.32 EPS, Q4 2027 earnings at $0.47 EPS, FY2027 earnings at $1.27 EPS and FY2028 earnings at $1.73 EPS.

Omnicell (NASDAQ:OMCL) last posted its earnings results on Thursday, July 30th. The company reported $0.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.47. The company had revenue of $312.21 million for the quarter, compared to analysts’ expectations of $310.21 million. Omnicell had a return on equity of 5.66% and a net margin of 3.13%.Omnicell’s quarterly revenue was up 7.4% on a year-over-year basis. During the same period last year, the firm earned $0.45 earnings per share. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS.

OMCL has been the topic of several other research reports. Weiss Ratings reiterated a “hold (c-)” rating on shares of Omnicell in a report on Tuesday, August 4th. Wells Fargo & Company cut their target price on shares of Omnicell from $55.00 to $50.00 and set an “overweight” rating on the stock in a research note on Friday, July 31st. KeyCorp lowered their price objective on shares of Omnicell from $70.00 to $65.00 and set an “overweight” rating for the company in a report on Friday, July 31st. Piper Sandler reiterated an “overweight” rating and set a $45.00 target price (down from $55.00) on shares of Omnicell in a report on Monday, August 3rd. Finally, Craig Hallum reissued a “buy” rating and issued a $55.00 target price on shares of Omnicell in a research report on Wednesday, April 29th. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Omnicell presently has an average rating of “Moderate Buy” and an average price target of $57.86.

Omnicell Price Performance

Shares of OMCL stock opened at $35.97 on Wednesday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.43 and a current ratio of 1.64. Omnicell has a fifty-two week low of $29.06 and a fifty-two week high of $55.00. The firm has a market cap of $1.64 billion, a P/E ratio of 42.82, a P/E/G ratio of 1.01 and a beta of 0.98. The business’s 50 day moving average price is $40.50 and its 200-day moving average price is $39.89.

Institutional Investors Weigh In On Omnicell

A number of institutional investors have recently modified their holdings of OMCL. Raymond James Financial Inc. bought a new position in shares of Omnicell during the second quarter valued at $26,000. Versant Capital Management Inc increased its stake in Omnicell by 38.7% during the 2nd quarter. Versant Capital Management Inc now owns 1,053 shares of the company’s stock valued at $44,000 after purchasing an additional 294 shares in the last quarter. Clearstead Advisors LLC raised its holdings in Omnicell by 12,180.0% in the fourth quarter. Clearstead Advisors LLC now owns 1,228 shares of the company’s stock worth $56,000 after buying an additional 1,218 shares during the last quarter. Kemnay Advisory Services Inc. purchased a new position in Omnicell in the fourth quarter worth about $58,000. Finally, Parkside Financial Bank & Trust lifted its stake in shares of Omnicell by 1,708.1% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,338 shares of the company’s stock worth $61,000 after buying an additional 1,264 shares in the last quarter. 97.70% of the stock is owned by hedge funds and other institutional investors.

Omnicell News Summary

Here are the key news stories impacting Omnicell this week:

• Positive Sentiment: Zacks raised its FY2026 EPS estimate to $1.49 from $1.27, above the broader consensus estimate of $1.30. It also increased its Q4 2027 forecast to $0.47 from $0.37 and FY2028 forecast to $1.73 from $1.71, suggesting some longer-term earnings potential.
• Neutral Sentiment: Zacks’ updated estimates call for FY2027 EPS of $1.27, FY2028 EPS of $1.73, and current-year consensus EPS of $1.30. The revisions indicate uncertainty about the timing and durability of Omnicell’s earnings growth.
• Negative Sentiment: Near-term estimates were cut across several periods: Q3 2026 EPS to $0.25 from $0.27, Q4 2026 to $0.07 from $0.31, Q1 2027 to $0.25 from $0.31, and Q2 2027 to $0.23 from $0.32. The sharp Q4 2026 reduction is particularly negative because it implies weaker profitability in the upcoming quarter.
• Negative Sentiment: Zacks lowered its FY2027 EPS forecast to $1.27 from $1.34. Combined with the firm’s “Strong Sell” rating, the revisions reinforce concerns about Omnicell’s near-term earnings trajectory despite the higher FY2026 estimate.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.